Clinical Trial Update: Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 or A*02-positive Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A safety and efficacy study of an epitope peptide for HLA-A*24 or A*02-positive advanced solid tumors has completed Phase 1/Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Epitope Peptide

Snippet

Sponsor: Shiga University | Conditions: Solid Tumors | Phase 1, Phase 2 | Status: COMPLETED